Abstract:Background and objective: Research has confirmed that transforming growth factor-beta1 (TGF-beta1) is one of the cytokines related to radiation pneumonitis. But the level of TGF-beta1 in serum needed to predict radiation pneumonitis is still not clear. This study assessed the value of TGF-beta1 in both serum and induced sputum in predicting radiation pneumonitis, providing a reference for the radiotherapy of patients with non-small cell lung cancer (NSCLC). Methods: A total of 23 patients with NSCLC treated with three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) in our department between November 2007 and January 2009 were analyzed and evaluated. TGF-beta1 levels in both serum and sputum were detected before and near the end of radiotherapy for all the patients. The TGF-beta1 level in serum was measured with enzyme-linked immunosorbent assay (ELISA). Immunocytochemistry assays were used to detect TGF-beta1 expression in sputum sediment. Radiation pneumonitis was graded according to Radiation Therapy Oncology Group (RTOG) radiation scoring criteria every 3 weeks from the start to 3 months after the end of treatment. Results: Radiation pneumonitis was noted in 9 patients in this cohort. The total incidence of radiation pneumonitis was 39.1% (9/23) and those with Grade II or worse was 30.4% (7/23). The absolute TGF-beta1 level in serum after radiotherapy was higher than before radiotherapy, but there was no statistical difference (P = 0.139). Patients with increased levels of TGF-beta1 had a higher incidence of radiation pneumonitis (45.5%) than those with decreased TGF-beta1 levels post-radiotherapy (40.0%). Though there was a tendency of higher incidence of radiation pneumonitis with increases in TGF-beta1 level, no statistical difference was found (P = 1.000). Patients with tumor response had higher incidence of radiation pneumonitis (50.0%) than patients without when TGF-beta1 levels in serum increased, but there was no statistical difference (P = 0.792). TGF-beta1 was positively expressed (brown yellow) in sputum on immunocytochemistry assays and located in the cytoplasm of either macrophages or epithelial cells. Macrophages were the main cells expressing TGF-beta1. A significantly higher positive expression rate (71.4%) was found in sputum post-radiotherapy than pre-radiotherapy (28.6%) (P = 0.015). The higher incidence of radiation pneumonitis (46.7%) was found in patients with positive TGF-beta1 expression in sputum post-radiotherapy than those with negative expression post-radiotherapy (14.3%) (P = 0.193). Conclusion: It may be more reasonable to predict radiation pneumonitis by combining the change of TGF-beta1 levels in serum with tumor response than just the change of TGF-beta1 levels in serum alone. TGF-beta1 can positively express in the sputum of patients with NSCLC, located in macrophages and epithelial cells, with macrophages as the main areas of expression. Patients with positively expressed TGF-beta1 in sputum after radiotherapy have a higher incidence of radiation pneumonitis than those with negative expressions. The positive expression of TGF-beta1 in sputum is expected to become a factor for predicting radiation pneumonitis.

Factors related to the incidence of CTCAE 3.0 Grade 2 or worse pulmonary fibrosis induced by neoadjuvant platinum-based chemotherapy and thoracic radiotherapy: A prospective study: P3-203

Inflammation Index Predicts Radiation-Induced Lung Injury and Prognosis in Lung Tumors Treated with Stereotactic Body Radiation Therapy

P2-223: Analysis of Clinical and Dosimetric Factors Associated with Severe Radiation Pneumonitis in Locally Advanced Non–Small–Cell–Lung–Cancer Patients Treated with Concurrent Chemotherapy and Intensity–modulated Radiotherapy (IMRT)

TGF-beta1 in serum and induced sputum for predicting radiation pneumonitis in patients with non-small cell lung cancer after radiotherapy

Predicting Severe Radiation Pneumonitis in Patients with Locally- Advanced Non-Small Cell Lung Cancer after Thoracic Radiotherapy: Development and Internal Validation of a Nomogram Based on the Clinical, Hematological and Dose–volume Histogram Parameters

Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).

Primarily Analysis of Radiation Pneumonitis and Its Risk Factors in Patients with Non-Small Cell Lung Cancer Treated with Concurrent Erlotinib and Thoracic Radiation Therapy

Analysis of clinical and dosimetric factors associated with radiation pneumonitis in patients with lung cancer or esophageal cancer treated with intensity-modulated radiotherapy

A Study of Ethnic Differences in TGFβ1 Gene Polymorphisms and Effects on the Risk of Radiation Pneumonitis in Non–Small-Cell Lung Cancer

Abstract 3626: Inflammation-related Genetic Variants Predict Radiation-Induced Toxicity Following Definitive Radiotherapy for Non-Small Cell Lung Cancer.

Preliminary analysis of the risk factors for radiation pneumonitis in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy

TGFβ1 Gene Polymorphisms with the Risk of Radiation Pneumonitis in Non-Small Cell Lung Cancer in Different Ethnic Study.

Combing NLR, V20 and Mean Lung Dose to Predict Radiation Induced Lung Injury in Patients with Lung Cancer Treated with Intensity Modulated Radiation Therapy and Chemotherapy

Risk Factors for Radiation Induced Lung Toxicity in Locally Advanced Non-Small Cell Lung Cancer Treated with Three-Dimensional Radiotherapy

Nondosimetric Biomarker of Serum Transforming Growth Factor-β1 Change after Neoadjuvant Chemoradiation Therapy Predicts Postoperative Pulmonary Complications in Esophageal Cancer Patients Receiving Combined Modality Therapy

Poster PresentationSimple Clinical Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy in Lung Cancer: A Pooled Analysis of 70 Studies: Treatment Toxicity

Alleviating lung injury and pulmonary fibrosis in radiotherapy-immunotherapy combination: The role of low-dose radiation therapy.

Serum Inflammatory Factors in Radiation Pneumonitis Patients Induced by Three-Dimensional Conformal Radiotherapy and Chemotherapy of Lung Cancer

Neutrophil‑to‑lymphocyte Ratio Reflects Lung Injury in Thoracic Radiotherapy and Immune Checkpoint Inhibitors Combination Therapy with Different Sequences.

Predicting Prognosis and Adverse Events by Hematologic Markers in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer